OOOdile Oberlin

Odile Oberlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Odile Oberlin has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Medulloblastoma in childhood: What effects on neurocognitive functions?

    by J. Khalil, S. Chaabi, O. Oberlin, S. Sialiti, L. Hessissen, N. Benjaafar


  • Screening for psychological distress in very long-term adult survivors of childhood cancer

    by Astrid de Laage, Rodrigue Allodji, Sarah Dauchy, Sophie Rivollet, Chiraz Fayech, Brice Fresneau, Odile Oberlin

    This study evaluated the prevalence of psychological distress (PD) in a cohort of 348 adult childhood cancer survivors with a very long-term follow-up and assessed the characteristics associated with this distress (cancer type, treatment, sex, age at diagnosis, self-reported late effects, social support, type of remembrance, time since the diagnosis, age at evaluation), assuming that with time since the diagnosis, the PD of survivors will approximate that of the general population. Before attending a long-term follow-up consultation, survivors were sent 3 questionnaires: the Brief Symptom Inventory-18, the Impact of Event Scale, and the Illness Worry Scale (IWS). During the visit, they were administered the Mini-International Neuropsychiatric Interview (MINI) by a psychologist. The mean age of the survivors was 38.5 years (18.1–65.8) at consultation, 7 years (0.0–18.0) at cancer diagnosis, and mean time since diagnosis was 31.5 years (8.8–56.1). Multiple regression analyses of the data collected from self-administered questionnaires confirmed that being female, living alone, and self-reported late effects were associated with the high scores for all scales. Negative remembrances and being accompanied to the clinic were associated with higher IWS scores. Unlike the initial hypothesis, the MINI showed that, compared with controls, survivors experienced a higher prevalence of anxiety and mood disorders even after a very long time since the diagnosis. These findings show that a substantial subset of survivors experiment a high prevalence of PD, higher than the general population, and should be screened for PD whatever the time since the diagnosis.


  • Efficacy of busulfan-melphalan high dose chemotherapy consolidation (BuMel) in localized high-risk Ewing sarcoma (ES): Results of EURO-EWING 99-R2 randomized trial (EE99R2Loc).

    by Jeremy Whelan, Marie-Cecile Le Deley, Uta Dirksen, Ian Robert Judson, Douglas S. Hawkins, Hendrik Van Den Berg, Ruth Ladenstein, Jarmila Kruseova, Andreas Ranft, Susanne Amler, et al.

    11000 Background: EE99R2Loc (ISRCTN61438620) was conducted in 12 countries, by 4 cooperative groups: GPOH, SFCE/GSF, UK-CCLG, and EORTC. It evaluated effects on event-free (EFS, main endpoint) and overall survival (OS) of BuMel compared to standard chemotherapy in ES presenting with localized disease and either a poor histologic response to induction chemotherapy or large tumor volume ( > 200ml) unresected or initially resected. Methods: Eligible pts were aged < 50, received 6 VIDE courses (vincristine, ifosfamide, doxorubicin, etoposide) and 1 VAI (vincristine, actinomycin-D, ifosfamide) before randomization to BuMel with stem cell rescue or VAI x 7 courses. The estimate of hazard ratio (HR) and the p-value were corrected for the 4 previous interim analyses by the Inverse Normal Method. Results: Between 2000 and 2013, from 477 pts classified as high-risk pts, 216 pts (median age, 17 yrs) were randomized to VAI (107) or BuMel (109). Some pts requiring radiation therapy (RT) to the primary site were excluded to avoid excess organ toxicity from interaction between RT and Busulfan. 80% entered the trial because of poor histologic response after chemotherapy alone. Median follow up is 8.0 yrs, with only 3 pts lost to follow up before 3 yrs. Overall, 3yr EFS is 60.0% and OS, 73.9%. In an intention to treat analysis, the risk of an event was significantly decreased by BuMel compared to VAI: HR = 0.63 (95%CI, 0.42-0.94) p = .023 ; 3yr-EFS of 66.9% (57.6-75.0) vs. 53.1% (43.6-62.3). OS also favored BuMel, 77.8 vs. 69.9%, HR = 0.60 (0.39-0.92) p = .019. Results were consistent across subgroups, and in sensitivity analyses. Two pts died of BuMel-related toxicity and 1 after standard chemotherapy. Significantly more BuMel pts experienced severe acute toxicities, but these arose from a single high-dose course vs. multiple VAI courses. Conclusions: BuMel conferred improvement in EFS and OS with acceptable toxicity for pts with localized ES and poor histological response to chemotherapy or large tumor volume unresected or initially resected. It should be considered as a standard of care for this group of pts with localized high-risk ES and no contra-indication to BuMel. Clinical trial information: 61438620.


  • Open Access

    Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups

    by Odile Oberlin, Annie Rey, Kenneth L.B. Brown, Gianni Bisogno, Ewa Koscielniak, Michael C.G. Stevens, Douglas S. Hawkins, William H. Meyer, Trang H. La, Modesto Carli, et al.

    Background Extremity rhabdomyosarcomas do not always show satisfactory outcomes. We analyzed data from 643 patients treated in 14 studies conducted by European and North American groups between 1983 and 2004 to identify factors predictive of outcome. Procedure Clinical factors, including age; histology; site of primary (hand and foot vs. other); size; invasiveness (T stage); nodal involvement (N stage); and treatment factors, including post‐surgical group; chemotherapy type and duration; radiotherapy; and treatment (before or after 1995); were evaluated for impact on overall survival (OS). Results 5‐year OS were 67% (se 1.8). Multivariate analysis showed that lower OS correlated with age >3 years, T2 and N1 stage, incomplete initial surgery, treatment before 1995, and European cooperative group treatment. Patients with gross residual disease after initial incomplete resection/biopsy had similar outcomes in both continental groups. The better global survival of patients treated in American studies was accounted for by differences in outcome in the subset of those with grossly resected tumors (OS 86% [se 3] for COG patients vs. 68% [se 4] for European patients (P = 0.004)). When excluding chemotherapy duration from the model, analysis in this subset of patients showed that cooperative group (P = 0.001), site (P = 0.001), and T stage (P = 0.05) were all significant. However, after adding duration of chemotherapy (≥27 weeks) to the model, only primary site remained significant (P = 0.006). Conclusion This meta‐analysis confirms the role of many established prognostic factors but identifies for the first time that chemotherapy duration may have an impact on outcome in patients with grossly resected tumors. Pediatr Blood Cancer


  • Educational trajectories after childhood cancer: When illness experience matters

    by A. Dumas, I. Cailbault, C. Perrey, O. Oberlin, F. De Vathaire, P. Amiel


  • In Memoriam—Jean Lemerle (1930–2014)

    by Odile Oberlin, Mhamed Harif, Giorgio Perilongo, Dominique Valteau‐Couanet, Giulio J. D'ANgio, Catherine Patte


  • Open Access

    Concomitant chemo‐radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: A case–control study

    by Sylvie Guérin, Catherine Guibout, Akthar Shamsaldin, Marie‐Gabrielle Dondon, Ibrahima Diallo, Mike Hawkins, Odile Oberlin, Olivier Hartmann, Jean Michon, Marie‐Cécile Le Deley, et al.

    Radiotherapy and chemotherapy are associated with an increased risk of a second malignant neoplasm (SMN) after a cancer during childhood. This study specified the dose‐effect relationship between radiotherapy, chemotherapy and the risk of a SMN, and investigated the effect of chemo‐radiotherapy on the risk of SMN. A case–control study nested in a European cohort of 4,581 patients treated for a solid cancer during childhood was conducted. One hundred and fifty three cases with a SMN and 442 controls were matched according to sex, age at first cancer, calendar year, type of first cancer and follow‐up. The local radiation dose was estimated at the site of the SMN, for each case and at the same site, for the matched controls. The local dose of radiation significantly increased the risk of a SMN. The best model was linear with an excess relative risk per Gray equal to 0.13 (95% CI, 0.06; 0.26). Any chemotherapy significantly increased the risk of a SMN, odd ratioadjusted (ORadjusted) = 2.4 (95% confidence interval (95% CI), 1.4–4.1), but no dose‐effect relationship was observed between any drug category and the risk of a SMN. Patients who had received concomitant chemo‐radiotherapy were significantly more at risk of developing a SMN than patients who had been treated with sequential chemo‐radiotherapy, even after adjustment for the local dose of radiation and the 6 most frequently administered drugs, ORadjusted = 2.3 (95%CI, 1.1–4.8). Radiation was found to be the foremost treatment‐related risk factor for the occurrence of a SMN. Compared to sequential treatment, concomitant chemo‐radiotherapy may lead to a higher risk of a SMN.